, Détection de fractions mutées élevées (>1%)
, Le coefficient de corrélation R entre valeurs théoriques et observées, était optimal pour l'ADNg, un peu moins pour l'ADNc. Références
, Blood, vol.129, issue.4, pp.424-448, 2017.
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia The Cancer Genome Atlas Research Network, N Engl J Med, 2013. ,
Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif, 2017. ,
Acute Myeloid Leukemia, N Engl J Med, 2015. ,
Nucleophosmin: From structure and function to disease development, BMC Mol Biol, vol.17, issue.1, pp.1-12, 2016. ,
Biological and clinical consequences of NPM1 mutations in AML, Leukemia, vol.31, issue.4, pp.798-807, 2017. ,
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: Molecular basis and clinical implications, Leukemia, 2009. ,
DOI : 10.1038/leu.2009.124
URL : http://www.nature.com/leu/journal/v23/n10/pdf/leu2009124a.pdf
PCR digitale en micro-compartiments, vol.31, pp.84-92, 2015. ,
Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms, Ann Lab Med, vol.38, issue.2, p.147, 2018. ,
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype, Blood, 2005. ,
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype, N Engl J Med, 2005. ,
DOI : 10.1056/nejmoa041974
URL : http://www.nejm.org/doi/pdf/10.1056/NEJMoa041974
Defining minimal residual disease in acute myeloid leukemia: Which platforms are ready for "prime time, Blood, 2014. ,
DOI : 10.1182/asheducation-2014.1.222
URL : http://asheducationbook.hematologylibrary.org/content/2014/1/222.full.pdf
Molecular landscape in acute myeloid leukemia: where do we stand in 2016, Cancer Biol Med, vol.13, issue.4, p.474, 2016. ,
DOI : 10.20892/j.issn.2095-3941.2016.0061
URL : http://www.cancerbiomed.org/index.php/cocr/article/download/985/1033
Genomic Classification and Prognosis in Acute Myeloid Leukemia, N Engl J Med, vol.374, issue.23, pp.2209-2221, 2016. ,
Genomics of acute myeloid leukemia diagnosis and pathways, J Clin Oncol, vol.35, issue.9, pp.934-946, 2017. ,
Cancer statistics, CA Cancer J Clin, vol.68, issue.1, pp.7-30, 2018. ,
DOI : 10.3322/caac.21208
Estimation nationale de l'incidence des cancers en France entre 1980 et 2012_Etude à partir des registres des, cancers du réseau Francim. InVS, 2013. ,
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, vol.129, pp.424-448, 2017. ,
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in Leukemia, Cell, vol.157, issue.2, pp.369-381, 2014. ,
Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist?, Br J Haematol, vol.161, issue.4, pp.541-550, 2013. ,
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome, Blood, vol.113, issue.13, pp.3088-3091, 2009. ,
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features ,
DOI : 10.1038/leu.2016.126
, Leukemia, vol.30, p.2282, 2016.
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity, Blood, vol.119, issue.20, pp.4719-4722, 2012. ,
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA, Blood, vol.122, issue.9, pp.1576-1582, 2013. ,
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features, Blood, vol.114, issue.14, pp.3024-3032, 2009. ,
, Sciences R. HHS Public Access, vol.70, issue.12, pp.773-779, 2016.
Signi fi cance of FAB subclassi fi cation of " acute myeloid leukemia , NOS " in the 2008 WHO classi fi cation : analysis of 5848 newly diagnosed patients, Bloodjournal.org, vol.121, issue.13, pp.2424-2432, 2015. ,
Granulocytic sarcoma: a systematic review, Am J Blood Res, vol.3, issue.4, pp.265-270, 2013. ,
Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome, Semin Fetal Neonatal Med, 2012. ,
The landscape of somatic mutations in Down syndrome-related myeloid disorders, Nat Genet, 2013. ,
outcome in 100 patients defined according to the WHO 2008 classification Mixed-phenotype acute leukemia : clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification, vol.117, pp.3163-3171, 2014. ,
Acute leukemias of ambiguous lineage: Diagnostic consequences of the WHO2008 classification, Leukemia, 2010. ,
Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status ,
, Int J Hematol, 2014.
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group, Br J Haematol, vol.33, issue.4, pp.451-458, 1976. ,
Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10, Leukemia, vol.25, issue.4, pp.567-574, 2011. ,
Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia, Blood, vol.124, issue.2, pp.273-276, 2014. ,
Acquired mutations in ASXL1 in acute myeloid leukemia: Prevalence and prognostic value, Haematologica, 2012. ,
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, Blood, 2012. ,
Acute Myeloid Leukemia: A Concise Review, J Clin Med, 2016. ,
Translational implications of somatic genomics in acute myeloid leukaemia, Lancet Oncol, 2014. ,
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia, Cancer Genomics Proteomics, 2016. ,
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia, Blood, 2008. ,
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome, Blood, 2009. ,
IDH mutation impairs histone demethylation and results in a block to cell differentiation, Nature, 2012. ,
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N Engl J Med, 2012. ,
DNMT3A mutations in acute myeloid leukemia, N Engl J Med, 2010. ,
Expression and prognostic impact of lncRNAs in acute myeloid leukemia, Proc Natl Acad Sci, 2014. ,
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia, Nature, 2014. ,
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A cancer and leukemia group B study, J Clin Oncol, 2011. ,
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics, Blood, 2011. ,
AML1 / RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia : prognostic implication and interaction with other gene alterations, Blood, vol.114, issue.26, pp.5352-5361, 2009. ,
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures, J Clin Oncol, 2012. ,
Dysregulation of the C/EBPalpha differentiation pathway in human cancer, J Clin Oncol, 2009. ,
The role of different genetic subtypes of CEBPA mutated AML, Leukemia, 2014. ,
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category, Blood, 2011. ,
AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients, Leuk Res, 2015. ,
The role of MLL in hematopoiesis and leukemia, Curr Opin Hematol, 2002. ,
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016. ,
A tumor suppressor and oncogene: The WT1 story, Leukemia, 2007. ,
Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases, J Cancer Res Clin Oncol, 2015. ,
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia, Blood, 2011. ,
Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A, Blood, 2013. ,
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years, Blood, 2005. ,
Targeting c-Kit mutations: Basic science to novel therapies, Leuk Res, 2004. ,
DOI : 10.1016/j.leukres.2003.10.004
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study, J Clin Oncol, 2006. ,
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia ,
, , 2006.
EZH2 in normal and malignant hematopoiesis, Leukemia, 2014. ,
DOI : 10.1038/leu.2013.288
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood, 2015. ,
DOI : 10.1182/blood-2014-11-610543
URL : http://www.bloodjournal.org/content/125/9/1367.full.pdf
Genetic alterations of the cohesin complex genes in myeloid malignancies, Blood, 2014. ,
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment, J Clin Oncol, 2011. ,
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia, Blood, 2016. ,
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance, Blood, 2016. ,
RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group ,
, J Clin Oncol, 2011.
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome, Leukemia, 2013. ,
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy, Blood, vol.121, issue.14, pp.2734-2738, 2013. ,
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia, Leukemia, 2013. ,
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, 2013. ,
Secondary genetic lesions in acute myeloid leukemia with inv (16) or t (16;16): a study of the German-Austrian AML Study Group (AMLSG), Blood, vol.121, issue.1, pp.170-178, 2013. ,
Comprehensive mutational profiling of core binding factor acute myeloid leukemia, Blood, 2016. ,
The genomic landscape of core-binding factor acute myeloid leukemias, Nat Genet, 2016. ,
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML, Blood, vol.114, issue.11, pp.2220-2231, 2009. ,
Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party, Blood, vol.131, issue.12, 2018. ,
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial ,
, J Clin Oncol, 2017.
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy, J Clin Oncol, 2009. ,
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: Results of the French CBF-2006 trial, Haematologica, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01817446
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial, Blood, 2012. ,
Wilms' tumor gene wt1: Its oncogenic function and clinical application, Int J Hematol, vol.73, issue.2, pp.177-187, 2001. ,
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial, Blood, vol.120, issue.14, pp.2826-2835, 2012. ,
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 2016. ,
Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalization, Protein Sci, 2013. ,
Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication, Nat Cell Biol, 2005. ,
Nucleophosmin Is Essential for Ribosomal Protein L5 Nuclear Export, Mol Cell Biol, 2006. ,
Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth, Biochemistry, 1989. ,
Mapping the functional domains of nucleolar protein B23, J Biol Chem, 2000. ,
Tryptophans 286 and 288 in the Cterminal region of protein B23.1 are important for its nucleolar localization, Biosci Biotechnol Biochem, 2002. ,
Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants, Cancer Res, 2007. ,
RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells, Oncogene, 2009. ,
Nucleophosmin regulates the stability and transcriptional activity of p53, Nat Cell Biol, 2002. ,
Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell, 2004. ,
Nucleolar Arf sequesters Mdm2 and activates p53, Nat Cell Biol, 1999. ,
N-terminal polyubiquitination and degradation of the Arf tumor suppressor, Genes Dev, 2004. ,
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia, Blood, 2006. ,
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations, Blood, 2005. ,
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML), Blood, 2006. ,
When the good go bad: Mutant NPM1 in acute myeloid leukemia, Blood Rev, vol.32, issue.3, pp.167-183, 2018. ,
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia, Blood, 2005. ,
Role of nucleophosmin in embryonic development and tumorigenesis, Nature, 2005. ,
Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant, Cancer Res, 2006. ,
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+AML, Blood, vol.107, issue.11, pp.4514-4523, 2006. ,
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse, Blood, 2008. ,
Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle, 2005. ,
Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and-8 inhibition, Blood, vol.116, issue.17, pp.3286-3296, 2010. ,
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification, Blood, 2006. ,
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype, Blood, 2005. ,
Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: Implications for the cell of origin of NPMc+ AML, vol.4 ,
, , 2008.
C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders, Br J Haematol, 2006. ,
Nucleophosmin mutations in de novo acute myeloid leukemia: The age-dependent incidences and the stability during disease evolution, Cancer Res, 2006. ,
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance, Blood, 2005. ,
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica, 2011. ,
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features, Blood, 2009. ,
DOI : 10.1182/blood-2009-01-197871
URL : http://www.bloodjournal.org/content/bloodjournal/114/14/3024.full.pdf
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome, J Clin Oncol, 2010. ,
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations, J Clin Oncol, 2010. ,
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia, N Engl J Med, 2008. ,
DOI : 10.1056/nejmoa074306
Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia, J Clin Oncol, 2015. ,
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML, Blood, 2013. ,
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1mutated patients identifies those at high risk of relapse, Haematologica, 2014. ,
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia, Blood, 2013. ,
Assessment of Minimal Residual Disease in Standard-Risk AML, N Engl J Med, 2016. ,
DOI : 10.1056/nejmoa1507471
URL : http://discovery.ucl.ac.uk/1475365/1/nejmoa1507471.pdf
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations ,
, Leukemia, vol.20, issue.6, pp.1103-1108, 2006.
A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers, BMC Genomics, 2012. ,
Monitoring of residual disease by nextgeneration deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease, Leukemia, 2014. ,
Quantitation of targets for PCR by use of limiting dilution, Biotechniques, 1992. ,
, Digital PCR. Genetics, 1999.
Current and Emerging Applications of Droplet Digital PCR in Oncology, Mol Diagn Ther, 2017. ,
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia, J Clin Med, 2017. ,
,
The digital MIQE guidelines: Minimum information for publication of quantitative digital PCR experiments, Clin Chem, 2013. ,
Megapixel digital PCR, Nat Methods, 2011. ,
DOI : 10.1038/nmeth.1640
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number, AnalChem, vol.83, pp.8604-8610, 2011. ,
DOI : 10.1021/ac202028g
URL : https://doi.org/10.1021/ac202028g
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics, Lab Chip, 2011. ,
DOI : 10.1039/c1lc20128j
Digital PCR for the molecular detection of fetal chromosomal aneuploidy, Proc Natl Acad Sci, 2007. ,
Evaluation of digital PCR for absolute DNA quantification, Anal Chem, 2011. ,
DOI : 10.1021/ac103230c
Mathematical analysis of copy number variation in a DNA sample using digital PCR on a nanofluidic device, PLoS One, 2008. ,
Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number, Anal Bioanal Chem, 2009. ,
PCR digitale en micro-compartiments pour la détection quantitative d 'ADN tumoral circulant, p.31, 2015. ,
Viral diagnostics in the era of digital polymerase chain reaction, Diagn Microbiol Infect Dis, 2013. ,
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin, Leukemia, vol.19, issue.10, pp.1760-1767, 2005. ,
Ultra-sensitive droplet digital PCR for detecting a low-prevalence somatic GNAQ mutation in Sturge-Weber syndrome, Sci Rep, vol.6, 2016. ,
DOI : 10.1038/srep22985
URL : https://www.nature.com/articles/srep22985.pdf
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: Results from the AML05 multicenter trial, Blood, vol.121, issue.20, pp.4056-4062, 2013. ,
Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: A study by the acute leukemia French association group, J Clin Oncol, vol.35, issue.2, pp.185-193, 2017. ,
Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia, J Mol Diagnostics, vol.19, issue.3, 2017. ,
DOI : 10.1016/j.jmoldx.2017.01.004
Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica. 2018:haematol, 2018. ,
DOI : 10.3324/haematol.2018.194712
URL : http://www.haematologica.org/content/early/2018/08/07/haematol.2018.194712.full.pdf
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia, Haematologica, 2018. ,
DOI : 10.3324/haematol.2017.186528
URL : http://www.haematologica.org/content/early/2018/03/16/haematol.2017.186528.full.pdf
Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia, Oncotarget, 2016. ,
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients, Ann Hematol, 2018. ,
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR, J Mol Diagn, 2015. ,
Analysis of minimal residual ,